Safety and tolerability of eprosartan.
The safety and tolerability of eprosartan were extensively assessed in 17 phase IIb-III studies that included 2709 patients with hypertension. The frequency of adverse events observed with eprosartan was similar to that seen with placebo. Neither the number nor the severity of these effects increased with prolonged therapy, and their frequency was not affected by increased eprosartan dosage or dosing frequency. The drug is equally well tolerated by women and men, by younger (< 65 yrs) and older (> or = 65 yrs) individuals, and by persons of all races. There are no known drug interactions, and eprosartan is well tolerated when given in combination with other frequently prescribed antihypertensive agents, without an increase in adverse events beyond those expected of baseline antihypertensive therapy.
Gavras
I
I
Department of Medicine, Hypertension and Atherosclerosis Section, Boston University School of Medicine, Massachusetts 02118, USA.
Gavras
H
H
D000179:Acrylates / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D013876:Thiophenes
D000179:Acrylates; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan